BMS Enters Clinical Supply and Collaboration Agreement to Support Dispatch Bio’s BCMA-Targeted CAR-T Combination Therapy for Solid Tumors

Note: This article does not constitute any investment opinions or recommendations; please refer to official/company announcements for accuracy. This article only provides an introduction to medical and health-related drugs, not a recommendation of treatment plans (if involved), and does not represent the platform's position.Any article reprinted must be authorized.

On November 4, Dispatch Bio, a biotechnology company developing universal therapies for solid tumors using its proprietary Flare platform, announced a clinical supply and collaboration agreement with Bristol-Myers Squibb (BMS) to support the development of Dispatch’s DISP-10 program. Under the agreement, BMS will provide idecabtagene vicleucel (ide-cel), a BCMA-targeted CAR-T therapy, for Dispatch's first U.S. Phase I clinical trial.The trial is expected to launch in 2026.

DISP-10 is a novel investigational product composed of two components, designed to address the challenges of solid tumor treatment. The first component, DV-10, is a tumor-specific virus genetically engineered to deliver modified B-cell maturation antigen (dBCMA), along with IL-18 and CXCL-9, to the surface of tumor cells. This "paints" synthetic antigens onto the tumor cells, reshaping the tumor microenvironment to support T-cell function and enhance T-cell migration into the tumor. The second component is ide-cel, Bristol-Myers Squibb's autologous CAR-T cell therapy targeting BCMA. In the planned study, patients with epithelial-derived solid tumors (accounting for 90% of all solid tumors) will first receive DV-10 treatment, followed by ide-cel treatment. Dispatch Biotherapeutics will lead and execute this research.

Reference: Company Announcement